FDA Accepts Neurocrine’s NDA for Parkinson’s Disease Drug – Zacks.com

FDA Accepts Neurocrine’s NDA for Parkinson’s Disease Drug – Zacks.com
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug  Zacks.comThe FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, ... read more
Source: Google NewsPublished on 2019-07-11